Summit Therapeutics PLC Sponsored ADR Aktie News

A company's comeback story can mean a significant opportunity for investors to win returns in the financial world. Of course, when a stock has shed a sizable portion of its value in recent memory, many investors prefer to exercise caution unless there is a clear signal that the firm's fortunes could turn around.

Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.

Summit Therapeutics' ivonescimab continues to ace phase 3 studies against approved drugs. The investigational cancer medicine could eventually become one of the world's best-selling therapies.

While insider buying is typically slower when markets are near all-time highs and when earnings-reporting season is in full swing, it never seems to dry up altogether.

Explore the exciting world of Summit Therapeutics (SMMT +2.83%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 26.68 million shares of the Company's common stock at $18.74 per share, the closing price on Tuesday, October 21, 2025, for ...

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2025 Earnings Call October 20, 2025 8:00 AM EDT Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West Mahkam Zanganeh - Co-CEO, President & Director Manmeet Soni - COO, CFO & Director Urte Gayko - Chief Regulatory, Quality & Pharmacovigilance Officer Allen Yang - Chief Medical Officer Robert Duggan - Co-CEO & Executiv...

Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically significant overall survival data. SMMT faces heightened financing risk due to increased trial enrollment and a limited cash runway, with dilution likely if partnerships don't materialize soon. The company's bold BLA strategy and expanded Phase 3 footprint increase binary risk, whi...